Author

Kuan-Chiao Tseng

Observed name: Kuan‐Chiao Tseng

Institution: PharmaEssentia Corporation (Taiwan)

Observed institution: PharmaEssentia Corporation (Taiwan)

ORCID: 0000-0003-1324-0911

Observed ORCID: 0000-0003-1324-0911

OpenAlex ID: A5110717758

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B

2020 · Yi-Wen Huang, Chao-Wei Hsu, et al. · Hepatology International · 30

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy

2021 · Hsien‐Hong Lin, Shih‐Jer Hsu, et al. · JGH Open · 22

Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C

2020 · Shih-Jer Hsu, Ming-Lung Yu, et al. · Journal of the Formosan Medical Association · 21

A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C

2022 · Chi‐Yi Chen, Wan‐Long Chuang, et al. · JGH Open · 14

Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results

2022 · Jin-Bon Hong, Po-Yuan Wu, et al. · Pharmaceutics · 7

Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study

2023 · Ming-Shen Dai, Ta-Chung Chao, et al. · Therapeutic Advances in Medical Oncology · 5

Works count: 6

Citation count: 99

H-index: 5

I10-index: 4